Investors showed strong interest in Ocugen (NASDAQ: OCGN) on Monday, driving the stock up by over 12% after the biotech company announced a licensing agreement with Kwangdong Pharmaceutical in South Korea for their drug targeting retinitis pigmentosa. The deal includes upfront fees and milestones worth up to $7.5 million, with potential for future sales milestones of $1.5 million for each $15 million in sales. With an estimated market of 7,000 RP patients in South Korea alone, Ocugen’s OCU400 drug could see significant success, potentially generating $180 million in sales within the first 10 years. Investors should explore other top stock options as recommended by the Motley Fool Stock Advisor team for potential high returns.

Read more at Nasdaq.: Why Ocugen Stock Zoomed 12% Higher Today